.jpg "IgA Secretory Component ECM1 IHC hu Colon Carcinoma (SPM217)")
PDF DatasheetHuman and Rat Anti-IgA Secretory Component / ECM1 Antibody Product Attributes
IgA Secretory Component / ECM1 Previously Observed Antibody Staining Patterns
Observed Subcellular, Organelle Specific Staining Data:
Anti-ECM1 antibody staining is expected to be primarily localized to the cytosol and nucleoplasm.
Observed Antibody Staining Data By Tissue Type:
Variations in IgA Secretory Component / ECM1 antibody staining intensity in immunohistochemistry on tissue sections are present across different anatomical locations. An intense signal was observed in glandular cells in the epididymis. More moderate antibody staining intensity was present in glandular cells in the epididymis. Low, but measureable presence of IgA Secretory Component / ECM1 could be seen inadipocytes in breast, chondrocytes in mesenchymal tissue, follicle cells in the ovary, glandular cells in the adrenal gland, cervix, uterine, seminal vesicle and thyroid gland, neuropil in cerebral cortex, peripheral nerve in mesenchymal tissue and respiratory epithelial cells in the bronchus and nasopharynx. We were unable to detect IgA Secretory Component / ECM1 in other tissues. Disease states, inflammation, and other physiological changes can have a substantial impact on antibody staining patterns. These measurements were all taken in tissues deemed normal or from patients without known disease.
Observed Antibody Staining Data By Tissue Disease Status:
Tissues from cancer patients, for instance, have their own distinct pattern of IgA Secretory Component / ECM1 expression as measured by anti-IgA Secretory Component / ECM1 antibody immunohistochemical staining. The average level of expression by tumor is summarized in the table below. The variability row represents patient to patient variability in IHC staining.
| Sample Type | breast cancer | carcinoid | cervical cancer | colorectal cancer | endometrial cancer | glioma | head and neck cancer | liver cancer | lung cancer | lymphoma | melanoma | ovarian cancer | pancreatic cancer | prostate cancer | renal cancer | skin cancer | stomach cancer | testicular cancer | thyroid cancer | urothelial cancer |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Signal Intensity | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| ECM1 Variability | ++ | ++ | + | + | + | + | + | + | + | + | + | + | ++ | + | + | + | + | + | ++ | + |
| IgA Secretory Component / ECM1 General Information | |
|---|---|
| Alternate Names | |
| Extracellular matrix protein 1, ECM1, EMC-1 | |
| Molecular Weight | |
| ~80kDa | |
| Chromosomal Location | |
| 1q21.2 | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | ECM1 |
| Entrez Gene ID | 1893 |
| Ensemble Gene ID | ENSG00000143369 |
| RefSeq Protein Accession(s) | NP_073155, NP_004416, NP_001189787 |
| RefSeq mRNA Accession(s) | NM_001202858, NM_022664, NM_004425 |
| RefSeq Genomic Accession(s) | NG_012062, NC_000001, NC_018912 |
| UniProt ID(s) | Q16610, A0A140VJI7 |
| UniGene ID(s) | Q16610, A0A140VJI7 |
| HGNC ID(s) | 3153 |
| Cosmic ID(s) | ECM1 |
| KEGG Gene ID(s) | hsa:1893 |
| PharmGKB ID(s) | PA27598 |
| General Description of IgA Secretory Component / ECM1. | |
| This MAb reacts with a reduction-resistant epitope present in both free, SIgA bound Secretory Component. It does not react with the cell lines lacking secretory component. The antibody is useful for studying the distribution, level of both free, bound secretory component. Secretory component is differentially expressed in epithelium,, the antibody is a popular marker for identifying subpopulations of epithelial cells, epithelial differentiation. The Secretory component antibody is a useful research tool for studying mucosal immunity, inflammation, remodeling, differentiation, tumorigenesis, all processes associated with differential secretory component expression. | |
-150x150.jpg)
-150x150.jpg)
There are no reviews yet.